In mouse models, GzmA knockout or inhibition reduced inflammation and CRC development, suggesting that development of effective GzmA inhibitors could offer therapeutic benefits treating gut inflammation and CRC. The gene discussed is GZMA; the disease is colorectal carcinoma.